Presence of allele HLA-C*12 which was found to be significantly associated with DLBCL risk in our study, was not associated with significantly different OS or PFS compared with patients with absence of HLA-C*12, p-value >0.05 (Figure 1). Here, HLA-C is linked to diffuse large B-cell lymphoma.